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Abstract
 
Bone marrow (BM)-derived antigen-presenting cells (APCs) are potent stimulators of T cell
immune responses. We investigated the requirements for antigen presentation by these cells in
priming cytotoxic T lymphocyte (CTL) responses to intracellular bacterial and viral patho-
 
gens. [Parent
 
®
 
F
 
1
 
] radiation BM chimeras were constructed using C57BL/6 donors and
 
(C57BL/6 
 
3
 
 BALB/c)F
 
1
 
 recipients. Infection of chimeric mice with either 
 
Listeria monocytoge-
nes
 
 or vaccinia virus expressing the nucleoprotein (NP) antigen from lymphocytic choriomen-
ingitis virus (LCMV) primed H2-D
 
b
 
–restricted, but not H2-K
 
d
 
–restricted CTL responses,
demonstrating the requirement for BM-derived APCs for successful priming of CTL responses
to these pathogens. Surprisingly, this did not hold true for chimeric mice infected with LCMV
itself. LCMV-infected animals developed strong CTL responses specific for both H2-D
 
b
 
– and
H2-L
 
d
 
–restricted NP epitopes. These findings indicate that in vivo priming of CTL responses
to LCMV is remarkably insensitive to deficiencies in antigen presentation by professional BM-
derived APCs.
Key words: cross-presentation • cytotoxic T cell • bacterial immunity • viral immunity • 
radiation chimera
 
Introduction
 
CD8
 
1
 
 CTLs recognize pathogen-derived peptides that are
presented on the surface of infected host cells by MHC
class I molecules. As MHC class I molecules are expressed
on nearly all nucleated cell types, appropriately stimulated
CTLs can lyse a variety of infected host cell types. Such
CTLs also produce cytokines such as IFN-
 
g
 
 and TNF-
 
a
 
,
which contribute to effective immune responses. A crucial
step in the generation of immunity to viral and bacterial in-
tracellular pathogens is thus the priming and activation of
pathogen-specific CTL responses.
Antigen presentation by specialized bone marrow (BM)
 
1
 
-
derived APCs can prime CTL responses in vitro and in
vivo. In particular, dendritic cells (DCs) are extremely effi-
cient at presenting antigens and priming T cell responses
(for a review, see reference 1). The efficiency of CTL
priming by DCs has been attributed in part to the expres-
sion of costimulatory molecules, including members of the
B7 (CD80/CD86) family (2). Expression of CD80/CD86
molecules is upregulated in cells treated with bacterial
components (3). Furthermore, the ability of APCs to co-
stimulate CD8
 
1
 
 T cell activation is enhanced after signals
delivered by activated CD4
 
1
 
 helper T cells or by infection
of DCs with viral pathogens (4–6). Thus, DCs or other
BM-derived APCs infected with intracellular viral patho-
gens appear to present antigens and prime CTL responses
in vivo.
Uninfected BM-derived APCs also prime CTL re-
sponses in infected or tumor-bearing animals. This phe-
nomenon, termed cross-priming, was first illustrated in
experiments in which CTL responses to minor histocom-
patibility antigens were primed in animals immunized with
cells that expressed the minor H antigens, but not the re-
stricting MHC alleles (7, 8). During cross-priming, anti-
gens from the immunizing cells are acquired and “cross-
presented” by the MHC class I molecules on the surface of
BM-derived APCs (9, 10). Cross-priming has been impli-
cated in the activation of CTL responses after immuniza-
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3
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1
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tion of radiation BM chimeras via intramuscular injection
of naked DNA (11–13), and via inoculation with nonhe-
matopoietic tumor cells (14, 15). Thus, abundant evidence
implicates BM-derived APCs in the priming and cross-
priming of CTL responses to a variety of nonreplicating
antigens.
Nonprofessional APCs have also been shown to be capa-
ble of priming CTL responses under some circumstances.
This conclusion stems from experiments demonstrating
that fibroblast cell lines can prime murine CTL responses
(16–18). In one set of experiments, fibroblasts that ex-
pressed lymphocytic choriomeningitis virus (LCMV) nu-
cleoprotein (NP) or glycoprotein antigens, but not known
costimulatory molecules, were shown to directly immunize
CTL responses to the LCMV antigens (18). Such priming
correlated with the fibroblasts reaching the spleen of inocu-
lated animals, suggesting that priming of CTL responses by
nonprofessional APCs selectively occurs within cytokine-
rich lymphoid environments (18). These results suggest that
infection with viral and intracellular bacterial pathogens
that induce inflammation within lymphoid tissues may
prime CTL responses independently of antigen presenta-
tion by BM-derived APCs.
In this study, we sought to address the role of BM-
derived professional APCs in the in vivo priming of CTL
responses to bacterial and viral pathogens that replicate
within the cytosol of non–BM-derived cell types. To this
end, the priming of CTL responses to pathogen-delivered
antigens in [Parent
 
®
 
F
 
1
 
] radiation BM chimeras was evalu-
ated after immunization with 
 
Listeria
 
 
 
monocytogenes
 
, LCMV,
or vaccinia virus. Our results indicate that antigen presenta-
tion by BM-derived APCs is essential for the priming of
CTL responses to 
 
L.
 
 
 
monocytogenes
 
 and vaccinia virus. In
contrast, CTLs restricted by both BM and parenchymal
MHC class I haplotypes were primed during infection with
LCMV. These data indicate that LCMV infection uniquely
facilitates priming of CTL responses in situations in which
there are profound deficiencies in antigen presentation by
BM-derived, professional APCs. We discuss potential
mechanisms to account for the radiation-resistant, host cell
presentation of LCMV.
 
Materials and Methods
 
Mice and Construction of Radiation Chimeras.
 
5–6-wk-old fe-
male C57BL/6 (B6) mice were purchased from Taconic Farms.
(BALB/c 
 
3
 
 B6)F
 
1
 
 (CB6) mice were purchased from The Jackson
Laboratory. All mice were housed under specific pathogen-free
conditions. To establish chimeras, recipient mice were irradiated
with a single dose (1,050 rads) from a 
 
137
 
Cs source. Within 24 h,
irradiated recipients were rescued by intravenous injection of 4 
 
3
 
10
 
6
 
 T cell–depleted BM cells isolated from the femurs of donor
mice. T cells were depleted from BM preparations by incubation
with a cocktail of anti-Thy1.2 (clone 30-H12), anti-CD8
 
a
 
 (clone
53-6.7), and anti-CD4 (clone GK1.5), followed by lysis with
low-tox-M rabbit complement (Cedarlane Labs). Chimeric ani-
mals were provided antibiotic water containing 13 mg/liter poly-
mixin B sulfate and 0.025 mg/liter neomycin sulfate for 4 wk af-
ter irradiation. At 4 wk after reconstitution, chimerism was
 
evaluated by the staining of PBLs with fluorochrome-labeled an-
tibodies. Similar levels of chimerism were obtained in all three
sets of chimeric animals used for the experiments described here.
Infections of chimeric animals were done between 6 and 12 wk
after BM reconstitution.
 
Cell Staining and FACS
 
®
 
.
 
Fluorochrome- or biotin-conju-
gated monoclonal antibodies to H2-K
 
b
 
 (AF6-88.5), H2-K
 
d
 
(SF1.1.1), and CD3-
 
e
 
 (145-2C11) were purchased from BD
PharMingen, as was an Fc receptor–blocking antibody (anti-
CD16/32; 2.4G2). Streptavidin-Tricolor was used as a secondary
reagent to detect biotinylated antibodies (Caltag). After osmotic
lysis of erythrocytes, samples of 10
 
6
 
 cells were incubated on ice
with saturating amounts of antibody in staining buffer (PBS, 3%
FCS, and 0.02% NaN
 
3
 
). Stained cells were fixed in a PBS/1%
paraformaldehyde solution before analysis on a FACScan™ (Bec-
ton Dickinson).
 
Infectious Agents. L
 
.
 
 monocytogenes
 
 EJL243 was provided by
Drs. Eric R. Jensen and Jeff F. Miller (University of California at
Los Angeles, Los Angeles, CA). This strain secretes the full-
length LCMV NP antigen and is derived from 
 
L
 
.
 
 monocytogenes
 
10403S (19). For infections, bacteria were thawed from stocks
stored at 
 
2
 
70
 
8
 
C and grown to mid-log phase (
 
A
 
600
 
 
 
z 
 
0.1) in
tripticase soy broth (Difco/Becton Dickinson). Log phase bacte-
ria were diluted in PBS for intravenous infection of chimeric
mice. CFUs present in inocula were determined by absorbance at
600 nm and by plating on tripticase soy broth/agar plates.
LCMV Armstrong 53b was originally obtained from Dr. Peter
Southern (University of Minnesota, Minneapolis, MN). Virus
was grown on BHK-21 cells (CCL-10; American Type Culture
Collection) and titred on Vero Cl008 cells (CRL-1586; Ameri-
can Type Culture Collection) as described previously (20). Re-
combinant vaccinia virus encoding the full-length LCMV NP
(VacNP) was obtained from Jonathan Yewdell (National Insti-
tutes of Health, Bethesda, MD). VacNP was grown on HeLa
cells and titred on Vero cells. Mice were infected intravenously
with LCMV or vaccinia virus diluted to the indicated PFU/ani-
mal in 200 
 
m
 
l PBS.
 
Peptides.
 
Peptides were synthesized on a Synergy apparatus
(Applied Biosystems/PerkinElmer), except for p60
 
(217–225)
 
, which
was synthesized by Research Genetics. Peptides were stored in
water or RPMI 1640 at 
 
2
 
20
 
8
 
C as 100–200 
 
m
 
M stocks.
 
Immunization with DCs.
 
DCs were enriched from spleens of
CB6 animals by low density centrifugation and an adherence/
deadherence procedure as described previously (21). DCs were
pulsed with synthetic listeriolysin O (LLO)
 
(91–99)
 
 peptide for 1 h,
and washed with RP10 media (RPMI 1640 with 10% heat-inac-
tivated FCS, 2 mM 
 
l
 
-glutamine, and antibiotics). DCs were re-
suspended in PBS and administered intravenously into naive chi-
meric animals.
 
CTL Assays.
 
For experiments with 
 
L
 
.
 
 monocytogenes
 
–infected
animals, responder splenocytes were harvested from immunized
animals and expanded 6 d ex vivo in cultures containing peptide-
pulsed stimulator cells. Stimulator cells were splenocytes har-
vested from naive CB6 mice pulsed for 2 h at 37
 
8
 
C in 1 ml RP10
containing a 1 
 
m
 
M concentration of the indicated stimulatory
peptide. Stimulator cells were irradiated (2,500 rads), washed in
RP10, and added at 3 
 
3
 
 10
 
7
 
 cells/flask to T-25 Falcon tissue cul-
ture flasks (Becton Dickinson) containing 3 
 
3
 
 10
 
7
 
 responder
splenocytes. Flasks were incubated upright for 6 d in a 7% CO
 
2
 
environment at 37
 
8
 
C in 10 ml RP10. Viable lymphoblastoid
cells, as determined by trypan blue exclusion, were used at indi-
cated E/T ratios in 4-h 
 
51
 
Cr-release assays. For the assays, P815
(H2
 
d
 
) and EL4 (H2
 
b
 
) target cells were labeled with 
 
51
 
Cr by a 
1137
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1–2-h incubation at 37
 
8
 
C, then washed and added to 96-well
plates in the presence of PBS or peptides diluted in PBS, as de-
scribed previously (22).
For experiments with LCMV and vaccinia virus–infected
mice, splenocyte effectors were harvested and washed twice in
PBS. After osmotic lysis of red blood cells, the effector cells were
washed twice more in PBS, counted, and resuspended at appro-
priate concentrations in a 1:1 mixture of RP10 and IMDM plus
10% FCS. For the assay, P815-D
 
b
 
 target cells were labeled by in-
cubation for 1 h with 
 
51
 
Cr with or without 1 
 
m
 
M of the indi-
cated peptides. Labeled target cells were washed and added to di-
lutions of effector cells for 6-h 
 
51
 
Cr-release assays.
In all CTL assays, supernatants were harvested and counted,
and the percentage of specific lysis was determined as described
previously (23). Target cells were maintained in RP10.
 
Results
 
Preliminary Analysis of Chimeras.
 
We reconstituted the
hematopoietic system of lethally irradiated CB6 recipient
mice with T cell–depleted BM from B6 donors. Radia-
tion-resistant cells in such chimeric animals express both
MHC haplotypes of the recipient (H2
 
d
 
 and H2
 
b
 
), whereas
radiation-sensitive BM-derived cells express only the donor
haplotype (H2
 
b
 
). The chimerism in BM-derived cell types
from naive, chimeric animals was evaluated by fluorescent
antibody staining of PBLs 4 wk after reconstitution. The
PBLs of irradiated CB6 animals reconstituted with CB6
BM ([CB6
 
®
 
CB6] chimeras) were 98.4 
 
6 
 
0.4% positive
for staining with a monoclonal antibody to H2-K
 
d
 
. In
contrast, this antibody failed to stain 87.3 
 
6 
 
2.2% of PBLs
from animals reconstituted with BM from B6 donors
([B6
 
®
 
CB6] chimeras). The difference between these
numbers indicates the approximate proportion of radiation-
resistant, recipient-derived PBLs which persisted in the
chimeric animals 4 wk after reconstitution (
 
z
 
11.1%). As
discussed below, the proportion of recipient-derived leu-
kocytes was even lower in the spleens of infected
[B6
 
®
 
CB6] chimeras (see Fig. 5 and below). These data in-
dicate that BM-derived cell types in the chimeric animals
were predominantly donor derived and express only the
donor H2
 
b
 
 antigen.
 
Parenchymal Cell Types Fail to Prime CTL Responses to L.
monocytogenes–delivered Antigens.
 
H2-D
 
b
 
– or H2-K
 
b
 
–restricted
CTL epitopes have not been identified in endogenous
 
 L
 
.
 
monocytogenes
 
 proteins. Thus, to determine the effects of
chimerism on priming of CTL responses to this intracel-
lular pathogen, we used a recombinant 
 
L
 
.
 
 monocytogenes
 
strain. The strain used, EJL243, expresses a secreted form of
the full-length NP antigen from LCMV, and was previ-
ously shown to immunize mice for CTL responses to NP
epitopes (19). We infected chimeric animals with an im-
munizing dose (
 
z
 
0.1 LD
 
50
 
) of 
 
L
 
.
 
 monocytogenes
 
 EJL243,
and 7–10 d later isolated immune splenocytes. These cells
were expanded in vitro and assayed for lysis of peptide-
pulsed target cells. The peptides used for pulsing correspond
to H2-K
 
d
 
–restricted epitopes from two secreted 
 
L
 
.
 
 mono-
cytogenes
 
 proteins, LLO and p60, and an H2-D
 
b
 
–restricted
epitope from the LCMV NP antigen. Lysis of P815 (H2
 
d
 
)
target cells coated with the LLO
 
(91–99)
 
 or p60
 
(217–225)
 
epitopes was readily apparent when effector cells were pre-
pared from [CB6
 
®
 
CB6] animals (Fig. 1, D and E). Thus,
CTL responses to these H2-K
 
d
 
–restricted epitopes were
 
 
 
ef-
ficiently primed in mice whose BM-derived APCs express
both H2
 
b
 
 and H2
 
d
 
 MHC alleles. CTL responses to an H2-
D
 
b
 
–restricted epitope from the NP antigen were also ob-
served in [CB6
 
®CB6] animals, as judged by specific lysis
of EL4 (H2b) target cells coated with the NP(396–404) peptide
(Fig. 1 F). However, such H2-Db–restricted responses were
observed in only a subset of the [CB6®CB6] animals
tested (Fig. 1 F, and data not shown), suggesting that re-
sponses to H2-Kd–restricted or other endogenous L. mono-
cytogenes epitopes dominate the response in such animals.
An inverse pattern of CTL responses was observed in
[B6®CB6] chimeric animals. In these animals, immuniza-
tion with the recombinant L. monocytogenes consistently
failed to prime H2-Kd–restricted CTL responses to either
Figure 1. BM MHC haplotype determines CTL priming after Listeria
infection. Three [B6®CB6] and three [CB6®CB6] chimeras were in-
fected with 500 CFU recombinant Listeria. Immune splenocytes were
stimulated in vitro with CB6 splenocytes coated with H2-Kd–restricted
Listeria LLO(91–99) (A and D) or p60(217–225) (B and E) epitopes or with the
H2-Db–restricted NP(396–404) epitope from the recombinantly expressed
NP of LCMV. CTL activity was assayed 6 d later using P815 (H2d) (A
and B, and D and E) or EL4 (H2b) (C and F) target cells coated with PBS
(open symbols) or with 20 nM of the indicated peptide (filled symbols).
Symbol types correspond to responder cells from individual mice. Similar
results were obtained in four additional experiments.1138 Bone Marrow APCs in CTL Priming to Intracellular Pathogens
the LLO(91–99) or the p60(217–225) epitopes (Fig. 1, A and B),
whereas CTL responses to the H2-Db–restricted NP(396–404)
epitope were readily detected (Fig. 1 C). These data indi-
cate that chimeric animals whose BM-derived APCs ex-
press only H2b fail to mount detectable H2-Kd–restricted
CTL responses to L. monocytogenes–delivered antigens. As
parenchymal cells of these animals are H2d3b, the selective
lack of responsiveness to the H2d epitopes suggests that
such parenchymal cells are quite ineffective at priming
CTL responses to L. monocytogenes.
Antigen Presentation by BM-derived APCs Is Required for
Priming of CTL Responses. A potential caveat to the above
experiments is the possibility that [B6®CB6] animals have
reduced numbers of H2d-restricted CTL precursors. A pau-
city of such precursors might arise from differences in thy-
mic selection in [B6®CB6] compared with [CB6®CB6]
chimeras. Alternatively, given the requirement for MHC
expression in the maintenance of naive T cells (for a re-
view, see reference 24), H2-Kd–restricted CTL precursors
might not persist in animals whose BM cells fail to ex-
press H2-Kd. Thus, we addressed the issue of whether
[B6®CB6] animals fail to select or maintain CTLs specific
for H2-Kd–restricted epitopes by assaying for such cells in
animals immunized with peptide-pulsed CB6 splenic
APCs. The APCs used were low density, DC-enriched
preparations pulsed in vitro with the LLO(91–99) peptide. Ef-
fector cells from the immunized animals lysed P815 target
cells coated with the LLO(91–99) peptide, but not target cells
presenting a control H2-Kd–restricted  L. monocytogenes
peptide (p60[217–225]). Thus, the immunization procedure
selectively primed CTL responses to the immunizing L.
monocytogenes–derived peptide (Fig. 2). These data demon-
strate the existence of CTL precursors specific for the
H2-Kd–restricted LLO(91–99) epitope in the [B6®CB6]
chimeric animals, and suggest that the failure of L. monocy-
togenes infection to prime H2-Kd–restricted responses in
such animals (Fig. 1) is not due to a deficiency in the selec-
tion or maintenance of H2-Kd–restricted CTLs. Rather,
the data indicate that the priming of CTL responses during
infection with L. monocytogenes, like the priming of CTL
responses in mice vaccinated with naked DNA (11–13), re-
quires antigen presentation by professional, BM-derived
APCs.
CTL Responses to LCMV Infection Are Not Dictated by the
Donor BM Haplotype. To investigate whether priming of
CTL responses to viral infection also requires antigen pre-
sentation by BM-derived APCs, we assayed for priming
of H2-Db– and H2-Ld–restricted CTL responses in
[CB6®CB6] and [B6®CB6] chimeras immunized with
LCMV. Splenocyte effector cells from animals immunized
with 105 PFU LCMV-Armstrong were tested directly ex
vivo for lysis of peptide-pulsed H2-Db–transfected P815
target cells (P815-Db). The effector cells from LCMV-
immune [CB6®CB6] chimeras efficiently lysed target cells
coated with either the H2-Ld–restricted NP(118–126) peptide
or the H2-Db–restricted NP(396–404) peptide (Fig. 3, D and
E). This result is consistent with priming of both H2b- and
H2d-restricted CTL populations by H2b3d BM-derived
APCs, and was predicted from the results of above experi-
ments using L. monocytogenes (Fig. 1, D–F). However, the
response pattern of the LCMV-infected [B6®CB6] chi-
meric animals was surprising. Such animals responded to
both the H2-Db–restricted epitope and the H2-Ld–
Figure 3. CTL priming during infection with LCMV is not dictated
by BM MHC haplotype. Three [B6®CB6] (A–C) and two [CB6®CB6]
(D and E) chimeras were infected intravenously with 105 PFU LCMV-
Armstrong. On day 9 after infection, ex vivo CTL activity was measured
directly using P815-Db target cells pulsed with PBS or with 1 mM of the
indicated NP peptide. NP(396–404) is presented by H2-Db and NP(118–126) is
presented by H2-Ld. The results in this figure are representative of three
experiments. A similar response pattern was observed in animals receiving
an LCMV inocula of only 200 PFU LCMV-Armstrong per animal.
Figure 2. Exogenous CB6 APCs can prime CTL responses to an H2-
Kd–restricted Listeria epitope in [B6®CB6] chimeras. DCs isolated from
spleens of CB6 mice were pulsed with 1 mM LLO(91–99) and used to im-
munize two naive [B6®CB6] chimeras intravenously. After 3 wk, sple-
nocytes from immunized chimeras were stimulated in vitro with LLO(91–99)
(left) or p60(217–225) (right) peptides. Responders were assayed after 6 d in
culture for lysis of P815 target cells coated with PBS (open symbols) or 50
nM of the corresponding peptide (filled symbols).1139 Lenz et al.
restricted epitope (Fig. 3, A–C). Identical results were ob-
served when mice were infected with lower doses (z200
PFU) of LCMV. These data indicate that LCMV infection
elicits priming of H2d-restricted CTL responses in animals
whose BM-derived cells are H2b. Thus, in sharp contrast to
the situation described above for responses to L. monocytoge-
nes infections, the CTL responses of LCMV-infected chi-
meric animals are not dictated by the MHC haplotype of
the donor BM.
Nonprofessional Antigen Presentation Is Not a Ubiquitous
Feature of Viral Infections. The data above suggest that
LCMV infection of [B6®CB6] chimeric animals leads to
priming of CTL responses that are restricted by parenchy-
mal cell MHC alleles. To determine whether infection
with a different viral pathogen could also induce similar
priming, we evaluated CTL responses after the infection of
chimeric animals with VacNP. As with LCMV infection,
CTL activity in spleens of VacNP-infected [B6®CB6]
and control [CB6®CB6] animals was assayed directly ex
vivo. Expectedly, [CB6®CB6] animals responded well to
the Ld-restricted NP(118–126) epitope (Fig. 4, C and D).
These animals responded poorly or not at all to the sub-
dominant H2-Db–restricted NP epitope. In contrast, in
[B6®CB6] animals, responses to the H2-Db epitope were
clearly seen but in no case did we observe responses to the
H2-Ld–restricted NP(118–126) epitope (Fig. 4, A and B). This
indicates that priming of CTL responses by parenchymal
cell types is not detected in the VacNP-infected animals,
similar to our findings with L. monocytogenes–infected ani-
mals (Fig. 1). Furthermore, these results indicate that the
apparently BM-independent priming of CTL responses af-
ter LCMV infection is not a general feature of infections
with viral pathogens and may rather be a specific feature of
LCMV infection.
Host-derived APC Populations Are Depleted Over 20-fold in
Chimeric Animals and Are Not Enriched upon LCMV Infec-
tion. The above data suggest that LCMV infection facili-
tates priming of CTL responses to antigen expressed by
nonprofessional APCs. However, the ability of [B6®CB6]
animals to generate strong CTL responses to the H2-Ld–
restricted NP epitope might also reflect presentation by re-
sidual BM-derived host APCs or selective recruitment or
expansion of host-derived professional APCs in the spleens
of LCMV-infected animals. To address these issues, we first
analyzed H2-Kd expression on CD31 and CD32 spleno-
cytes from LCMV-infected or VacNP-infected chimeric
mice. Representative results of this analysis appear in Fig. 5.
As expected, nearly all cells from infected [CB6®CB6] an-
imals stained positive with an antibody to H2-Kd. In con-
trast, only 6.5% of splenocytes from the VacNP-infected
[B6®CB6] animal expressed H2-Kd. A similar proportion
(5.5%) of cells was H2-Kd1 in the LCMV-infected spleen.
Furthermore, the majority of host-derived H2-Kd1 cells in
both sets of infected [B6®CB6] animals were CD31 T
cells. The reduced size (0.2%) of the H2-Kd1, CD32 popu-
lation in the LCMV-infected [B6®CB6] animal may be
explained by dilution of these cells by the three- to fourfold
greater expansion of T cells occurring in the spleens of
LCMV-infected animals. After accounting for this expan-
sion, the populations of H2-Kd1, CD32 splenocytes are
approximately equal in the LCMV-infected and VacNP-
infected animals. Thus, we fail to demonstrate any enrich-
Figure 5. Representation of H2-Kd–expressing APCs is similar in chi-
meric animals infected with recombinant vaccinia virus or LCMV. Sple-
nocytes from VacNP- or LCMV-infected [B6®CB6] chimeras were har-
vested on day 6 or 9 after infection, respectively. Cells were stained with
antibodies to CD3 and H2-Kd and analyzed by FACS®.
Figure 4. Recombinant vaccinia virus infection elicits CTL responses
only to epitopes presented by BM-derived APCs. Two [B6®CB6] (A
and B) and two [CB6®CB6] (C and D) chimeric mice were infected in-
travenously with 5 3 106 PFU of VacNP. 6 d after infection, CTL activ-
ity in spleens of infected mice was quantitated using P815-Db target cells
pulsed with 1 mM of the indicated NP peptides as described in the legend
to Fig. 2. Similar results were obtained in two additional experiments, and
were seen in animals infected with 7.1 3 106 PFU of VacNP.1140 Bone Marrow APCs in CTL Priming to Intracellular Pathogens
ment of host-derived BM APCs in LCMV-infected
animals. The proportion of chimerism in non-B, non-T
cell populations was also evaluated by triple staining sple-
nocytes for CD3, B220, and Kd. The CD31B2202,
CD32B2201, and CD32B2202 populations were of equal
size in [B6®CB6] and [CB6®CB6] animals, with the
CD32B2202 population, which includes DCs and mac-
rophages, comprising 3.6–5.8% of total splenocytes. How-
ever, the proportion of Kd1 cells in this CD32B2202 pop-
ulation differed substantially between the two groups of
animals, with z99.9% of this population (4.8–5.8% of total
splenocytes) staining positive for Kd in the [CB6®CB6]
chimeras, but only 3.5–5.5% (0.2–0.3% of total spleno-
cytes) staining for Kd in the [B6®CB6] chimeras. These
data suggest that professional Kd-restricted antigen presen-
tation is reduced z18–30-fold in the [B6®CB6] mice
compared with the [CB6®CB6] mice.
Discussion
We used radiation chimeras to investigate the require-
ment for professional, BM-derived APCs in the priming of
CTL responses to antigenic epitopes from three different
intracellular pathogens. Our data indicate that [B6®CB6]
chimeric animals infected with two of these pathogens gen-
erate only CTL responses restricted by the BM MHC hap-
lotype (H2b). Chimeric [B6®CB6] animals infected with
recombinant L.  monocytogenes bacteria or vaccinia virus
mounted strong H2-Db–restricted responses to recombi-
nantly expressed LCMV NP antigen, but were consistently
unresponsive to H2d-restricted epitopes from the same NP
antigen or from two endogenous L. monocytogenes proteins
(LLO and p60). The unresponsiveness was not attributable
to holes in the T cell repertoire of the radiation chimeras
used, as CTL responses to an H2-Kd–restricted L. monocytog-
enes–derived epitope could be induced in the [B6®CB6]
chimeras after in vivo priming with peptide-pulsed DCs,
and immunization with LCMV showed that the repertoire
was intact.
With regard to CTL priming after vaccinia virus infec-
tion, our results confirm those reported in a recent study by
Sigal et al. (25), who illustrated the importance of BM-
derived APCs in the priming and cross-priming of CTL
responses to recombinant vaccinia virus and poliovirus in-
fections. Furthermore, older studies had indicated that
priming of CTL responses to influenza (26) and vesicular
stomatitis virus (27) were abrogated in mice whose mac-
rophages were depleted by in vivo treatment with car-
rageenan, silica, or liposome-encapsulated toxins. Thus,
BM-derived APCs have now been implicated as essential
elements in the priming of CTL responses to at least four
viral pathogens.
It is well known that wild-type mice infected with L.
monocytogenes develop robust CTL responses to epitopes
from a small number of secreted endogenous or recombi-
nantly expressed bacterial antigens (19, 28). In contrast to
the above-mentioned viral infections, mechanisms for
priming of CTL responses to this and other bacterial patho-
gens are largely obscure. However, a study by Shen et al.
has shed some light on this subject (29). This study illus-
trated that a model antigen localized to the L. monocytogenes
cytosol efficiently primed antigen-specific CTL responses
in infected mice. Conversely, this antigen had to be se-
creted into the cytosol of infected cells to provide CTL-
mediated protection during the effector phase of anti-Liste-
ria immunity. The authors explained these differences in
the requirement for antigen secretion by demonstrating
that processing of nonsecreted bacterial antigens can occur
within macrophages. Thus, these and other professional
APCs are postulated to cross-prime CTL responses to non-
secreted L. monocytogenes antigens. In contrast, nonprofes-
sional APCs are unable to access and/or present antigens
that are not secreted by cytosolic L. monocytogenes, explain-
ing the requirement for antigen secretion in the effector
phase of CTL immunity (29). Our results with L. monocy-
togenes–infected chimeric animals are consistent with a cen-
tral role for BM-derived APCs in the priming of CTL re-
sponses to L. monocytogenes, as they provide the first direct
evidence that antigen presentation by BM-derived APCs is
essential for the priming of CTL responses to an intracellu-
lar bacterial pathogen.
In sharp contrast to our results with L. monocytogenes and
vaccinia virus, the priming of CTL responses in LCMV-
infected [B6®CB6] chimeric animals shows little require-
ment for antigen presentation by donor BM-derived APCs.
Both H2b- and H2d-restricted CTL responses were invari-
ably observed after infection of [B6®CB6] chimeric ani-
mals, even with very low (200 PFU/animal) viral inocula
(data not shown). These findings are somewhat at odds
with the conclusions of a previous report in which effector
cells from chimeric [k3b®d3b] animals failed to lyse
LCMV-infected H2d target cells after in vivo priming with
LCMV (30). However, the failure to detect H2d-restricted
responses in this case may have been due to other factors,
such as the use of infected (as opposed to peptide-pulsed)
target cells. In line with this explanation, adoptive transfer
experiments in that same study are more consistent with
the possibility that H2d-restricted CTL were indeed primed
to some extent in the [k3b®d3b] chimeras. Furthermore,
our findings with LCMV are confirmed and comple-
mented by results from Sigal and Rock reported in this is-
sue (31). As in our work, they find that CTL responses to
NP118/Ld in [b®d3b] BM chimeras are readily detected
in LCMV-infected animals (31). This response persisted
even after supralethal irradiation of host animals, although
even such extreme measures failed to completely eradicate
host-derived BM APCs. Thus, it becomes clear that CTL
priming during an LCMV infection, particularly to the
NP118/Ld epitope, is remarkably insensitive to the level of
antigen presentation by BM-derived APCs. Our own
staining results indicate that the population of host-derived
APCs that persist in [B6®CB6] chimeras is between 1/29
and 1/18 of that seen in [CB6®CB6] chimeras, and that
the ratio of chimerism is not altered after infection with
LCMV versus VacNP (see Fig. 5, and Results). These data
argue against enhanced survival or expansion of recipient-1141 Lenz et al.
derived (CB6) professional APCs in the LCMV-infected
chimeric mice. However, we cannot yet differentiate be-
tween priming of NP118/Ld responses by the small popu-
lation of host BM–derived APCs versus non–BM-derived
host cell types. Such priming is, however, remarkably effi-
cient. Thus, although the proportion of B2202CD32 sple-
nocytes expressing Kd is reduced by at least 20-fold in
[B6®CB6] animals, there is no observed reduction in the
level of CTL priming after LCMV infection (Fig. 3). This
contrasts sharply with the situation after L. monocytogenes
and vaccinia infections and leads us to conclude that unique
features of the LCMV infection make this pathogen more
efficient at stimulating CTL responses. What might these
features be?
First, LCMV may uniquely infect a subset of non–BM-
derived cells that constitutively prime host CTL responses.
However, this possibility seems unlikely because each of
the intracellular pathogens used in this study infects a broad
range of non–BM-derived host cell types in vitro. L. mono-
cytogenes, for example, has been shown to infect hepato-
cytes, epithelial, endothelial, and other adherent cell types,
such as fibroblasts, in vitro. Furthermore, bacteria have
been observed in splenic barrier cells (a fibroblastoid cell
type [32]) as well as in hepatocytes in tissue sections from
L. monocytogenes–infected mice (33). Although the precise
nature of all cell types infected by each of these pathogens
in vivo remains to be determined, the available evidence
suggests that infection of non-BM host cell types, even
within lymphoid organs, does not by itself facilitate BM-
independent priming of CTL responses to an intracellular
pathogen.
Second, LCMV infection may enhance the priming abil-
ity of H2d-expressing cells or otherwise lower the threshold
for activation of CTL precursors. Such enhancement could
affect priming by either BM-derived or parenchymal cell
types, perhaps by inducing expression of costimulatory fac-
tors that enhance their ability to prime naive CTLs. It is
clear from previous work that the priming of CTL re-
sponses to LCMV can occur independently of CD28 ex-
pression (34). We have also observed CD28-independent
priming of CTL responses restricted by both donor and re-
cipient haplotypes after LCMV infection of CB6 radiation
chimeras that were reconstituted with CD28-deficient
(H2b) BM (data not shown). These observations suggest
that additional, CD28-independent, costimulatory factors
contribute to priming of CTL responses during LCMV in-
fections, whether restricted by donor or host H2. We hy-
pothesize that selective upregulation of such factors during
LCMV infection, but not during L. monocytogenes or vac-
cinia infections, may account for the remarkably efficient
priming of CTL responses seen during LCMV infection.
Such novel costimulatory factors might act to modify either
the non–BM-derived APCs or the T cell. This hypothesis
is supported by recent data from Ochsenbein et al. (35).
These authors showed that mice immunized with LCMV
mount a protective memory response upon secondary chal-
lenge with LCMV that is more rapid and robust than the
memory response induced by immunization with a recom-
binant, NP epitope–expressing L. monocytogenes. This effect
was also seen upon adoptive transfer of equal numbers of
immune CTLs from animals primed with LCMV or with
NP-expressing L. monocytogenes. These results suggest that
CTLs immunized during an LCMV infection are more
protective on a per cell basis than are CTLs immunized to
the same antigen during a L. monocytogenes infection. Thus,
infection of mice with LCMV, as opposed to L. monocytoge-
nes (and presumably vaccinia virus), may induce a pro-
longed alteration in the threshold required for activation or
survival of antigen-specific CTLs. Such mechanisms may
also account for the profound differences in the burst size
of the primary, CTL response seen after LCMV infection
(36, 37) versus L. monocytogenes infection (28) of wild-type
animals. Further experiments will be required to test the
validity of this hypothesis.
The features of host–pathogen interactions that govern
the efficiency of CTL priming in vivo are not well under-
stood. Even when antigen is present in central lymphoid
organs, in most cases it must be presented by professional
APCs to prime effectively. LCMV appears to bend or per-
haps even break this rule, as CTL priming to LCMV-deliv-
ered antigen is completely insensitive to the profound re-
duction in antigen presentation by BM APC populations.
It will be important to better define the mechanisms for
“BM-insensitive” CTL priming during LCMV infection.
A better understanding of the mechanisms for CTL prim-
ing during infections should facilitate the development of
vaccines and immune therapies for important human
pathogens.
We thank L. Bogatzki for technical assistance, S. Martin and A.
Norment for discussions, A.Y. Rudensky for bone marrow from
CD28-deficient mice, and J. Yamagiwa for secretarial assistance.
This work was supported by grants from the National Institutes
of Health and the Howard Hughes Medical Institute.
Submitted: 19 June 2000
Revised: 17 August 2000
Accepted: 22 August 2000
References
1. Banchereau, J., and R.M. Steinman. 1998. Dendritic cells
and the control of immunity. Nature. 392:245–252.
2. Steinman, R.M. 2000. DC-SIGN: a guide to some mysteries
of dendritic cells. Cell. 100:491–497.
3. Lenschow, D.J., T.L. Walunas, and J.A. Bluestone. 1996.
CD28/B7 system of T cell costimulation. Annu. Rev. Immu-
nol. 14:233–258.
4. Ridge, J.P., F. Di Rosa, and P. Matzinger. 1998. A condi-
tioned dendritic cell can be a temporal bridge between a
CD41 T-helper and a T-killer cell. Nature. 393:474–478.
5. Bennett, S.R., F.R. Carbone, F. Karamalis, R.A. Flavell, J.F.
Miller, and W.R. Heath. 1998. Help for cytotoxic-T-cell re-
sponses is mediated by CD40 signalling. Nature. 393:478–
480.
6. Schoenberger, S.P., R.E. Toes, E.I. van der Voort, R. Of-
fringa, and C.J. Melief. 1998. T-cell help for cytotoxic T
lymphocytes is mediated by CD40-CD40L interactions. Na-1142 Bone Marrow APCs in CTL Priming to Intracellular Pathogens
ture. 393:480–483.
7. Bevan, M.J. 1976. Cross-priming for a secondary cytotoxic
response to minor H antigens with H-2 congenic cells which
do not cross-react in the cytotoxic assay. J. Exp. Med. 143:
1283–1288.
8. Bevan, M.J. 1976. Minor H antigens introduced on H-2 dif-
ferent stimulating cells cross-react at the cytotoxic T cell level
during in vivo priming. J. Immunol. 117:2233–2238.
9. Carbone, F.R., C. Kurts, S.R. Bennett, J.F. Miller, and
W.R. Heath. 1998. Cross-presentation: a general mechanism
for CTL immunity and tolerance. Immunol. Today. 19:368–
373.
10. Heath, W.R., and F.R. Carbone. 1999. Cytotoxic T lym-
phocyte activation by cross-priming. Curr. Opin. Immunol.
11:314–318.
11. Doe, B., M. Selby, S. Barnett, J. Baenziger, and C.M.
Walker. 1996. Induction of cytotoxic T lymphocytes by in-
tramuscular immunization with plasmid DNA is facilitated by
bone marrow-derived cells. Proc. Natl. Acad. Sci. USA. 93:
8578–8583.
12. Iwasaki, A., C.A. Torres, P.S. Ohashi, H.L. Robinson, and
B.H. Barber. 1997. The dominant role of bone marrow-derived
cells in CTL induction following plasmid DNA immuniza-
tion at different sites. J. Immunol. 159:11–14.
13. Corr, M., D.J. Lee, D.A. Carson, and H. Tighe. 1996. Gene
vaccination with naked plasmid DNA: mechanism of CTL
priming. J. Exp. Med. 184:1555–1560.
14. Huang, A.Y., A.T. Bruce, D.M. Pardoll, and H.I. Levitsky.
1996. In vivo cross-priming of MHC class I-restricted anti-
gens requires the TAP transporter. Immunity. 4:349–355.
15. Huang, A.Y., P. Golumbek, M. Ahmadzadeh, E. Jaffee, D.
Pardoll, and H. Levitsky. 1994. Role of bone marrow-derived
cells in presenting MHC class I-restricted tumor antigens. Sci-
ence. 264:961–965.
16. Sprent, J., and M. Schaefer. 1986. Capacity of purified Lyt-21
T cells to mount primary proliferative and cytotoxic re-
sponses to Ia2 tumour cells. Nature. 322:541–544.
17. Kosaka, H., C.D. Surh, and J. Sprent. 1992. Stimulation of
mature unprimed CD81 T cells by semiprofessional antigen-
presenting cells in vivo. J. Exp. Med. 176:1291–1302.
18. Kundig, T.M., M.F. Bachmann, C. DiPaolo, J.J. Simard, M.
Battegay, H. Lother, A. Gessner, K. Kuhlcke, P.S. Ohashi,
H. Hengartner, and R.M. Zinkernagel. 1995. Fibroblasts as
efficient antigen-presenting cells in lymphoid organs. Science.
268:1343–1347.
19. Shen, H., M.K. Slifka, M. Matloubian, E.R. Jensen, R.
Ahmed, and J.F. Miller. 1995. Recombinant Listeria monocy-
togenes as a live vaccine vehicle for the induction of protective
anti-viral cell-mediated immunity. Proc. Natl. Acad. Sci.
USA. 92:3987–3991.
20. Ahmed, R., A. Salmi, L.D. Butler, J.M. Chiller, and M.B.
Oldstone. 1984. Selection of genetic variants of lymphocytic
choriomeningitis virus in spleens of persistently infected
mice. Role in suppression of cytotoxic T lymphocyte re-
sponse and viral persistence. J. Exp. Med. 160:521–540.
21. Brossart, P., and M.J. Bevan. 1997. Presentation of exoge-
nous protein antigens on major histocompatibility complex
class I molecules by dendritic cells: pathway of presentation
and regulation by cytokines. Blood. 90:1594–1599.
22. Lenz, L.L., B. Dere, and M.J. Bevan. 1996. Identification of
an H2-M3-restricted Listeria epitope: implications for antigen
presentation by M3. Immunity. 5:63–72.
23. Butz, E.A., and M.J. Bevan. 1998. Differential presentation
of the same MHC class I epitopes by fibroblasts and dendritic
cells. J. Immunol. 160:2139–2144.
24. Goldrath, A.W., and M.J. Bevan. 1999. Selecting and main-
taining a diverse T-cell repertoire. Nature. 402:255–262.
25. Sigal, L.J., S. Crotty, R. Andino, and K.L. Rock. 1999. Cy-
totoxic T-cell immunity to virus-infected non-haematopoi-
etic cells requires presentation of exogenous antigen. Nature.
398:77–80.
26. Debrick, J.E., P.A. Campbell, and U.D. Staerz. 1991. Mac-
rophages as accessory cells for class I MHC-restricted im-
mune responses. J. Immunol. 147:2846–2851.
27. Ciavarra, R.P., K. Buhrer, N. Van Rooijen, and B. Tedes-
chi. 1997. T cell priming against vesicular stomatitis virus an-
alyzed in situ: red pulp macrophages, but neither marginal
metallophilic nor marginal zone macrophages, are required
for priming CD41 and CD81 T cells. J. Immunol. 158:1749–
1755.
28. Busch, D.H., I.M. Pilip, S. Vijh, and E.G. Pamer. 1998. Co-
ordinate regulation of complex T cell populations responding
to bacterial infection. Immunity. 8:353–362.
29. Shen, H., J.F. Miller, X. Fan, D. Kolwyck, R. Ahmed, and
J.T. Harty. 1998. Compartmentalization of bacterial antigens:
differential effects on priming of CD8 T cells and protective
immunity. Cell. 92:535–545.
30. Zinkernagel, R.M., G. Kreeb, and A. Althage. 1980. Lym-
phohemopoietic origin of the immunogenic, virus-antigen-
presenting cells triggering anti-viral T-cell responses. Clin.
Immunol. Immunopathol. 15:565–576.
31. Sigal, L.J., and K.L. Rock. 2000. Bone marrow-derived anti-
gen presenting cells are required for the generation of cyto-
toxic T lymphocyte responses to viruses and use transporter
associated with antigen presentation (TAP)-dependent and
-independent pathways of antigen presentation. J. Exp. Med.
192:1143–1150.
32. Weiss, L. 1991. Barrier cells in the spleen. Immunol. Today.
12:24–29.
33. Conlan, J.W., and R.J. North. 1994. Neutrophils are essen-
tial for early anti-Listeria defense in the liver, but not in the
spleen or peritoneal cavity, as revealed by a granulocyte-
depleting monoclonal antibody. J. Exp. Med. 179:259–268.
34. Shahinian, A., K. Pfeffer, K.P. Lee, T.M. Kundig, K. Kishi-
hara, A. Wakeham, K. Kawai, P.S. Ohashi, C.B. Thompson,
and T.W. Mak. 1993. Differential T cell costimulatory re-
quirements in CD28-deficient mice. Science. 261:609–612.
35. Ochsenbein, A.F., U. Karrer, P. Klenerman, A. Althage, A.
Ciurea, H. Shen, J.F. Miller, J.L. Whitton, H. Hengartner,
and R. M. Zinkernagel. 1999. A comparison of T cell mem-
ory against the same antigen induced by virus versus intracel-
lular bacteria. Proc. Natl. Acad. Sci. USA. 96:9293–9298.
36. Butz, E.A., and M.J. Bevan. 1998. Massive expansion of anti-
gen-specific CD81 T cells during an acute virus infection.
Immunity. 8:167–175.
37. Murali-Krishna, K., J.D. Altman, M. Suresh, D.J. Sourdive,
A.J. Zajac, J.D. Miller, J. Slansky, and R. Ahmed. 1998.
Counting antigen-specific CD8 T cells: a reevaluation of by-
stander activation during viral infection. Immunity. 8:177–
187.